Skip to content
InMed-logo-01
  • Science
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • IntegraSyn™ Cannabinoid Manufacturing
    • InMed’s Research of Rare Cannabinoids
  • Investor
  • About
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Corporate Governance
    • Partners and Collaborators
    • Events Calendar
    • Careers
  • Learn
    • What is Cannabinol (CBN)?
    • What is Epidermolysis Bullosa (EB)?
    • What is Glaucoma?
    • GMP Manufacturing Standards by Product Type
    • Cannabis Treatments for Glaucoma
    • Cannabinoid Science
    • Articles and Videos
  • Contact
Menu
  • Science
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • IntegraSyn™ Cannabinoid Manufacturing
    • InMed’s Research of Rare Cannabinoids
  • Investor
  • About
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Corporate Governance
    • Partners and Collaborators
    • Events Calendar
    • Careers
  • Learn
    • What is Cannabinol (CBN)?
    • What is Epidermolysis Bullosa (EB)?
    • What is Glaucoma?
    • GMP Manufacturing Standards by Product Type
    • Cannabis Treatments for Glaucoma
    • Cannabinoid Science
    • Articles and Videos
  • Contact
TSX_Logo
NASDAQ_Logo
Leader in the Therapeutic Development of Cannabinol (CBN)
InMed is the first company to advance the rare cannabinoid, cannabinol (CBN), into a clinical trial as a potential therapeutic to treat disease.
Learn More
INM-755 for Epidermolysis Bullosa
INM-755 is a cannabinol topical cream in development for the treatment of epidermolysis bullosa, a devastating genetic skin disease. InMed has completed two Phase 1 studies of INM-755 cream in healthy volunteers.
Learn More
Rare Cannabinoids for Ocular Diseases
INM-088 is a cannabinol formulation under development for glaucoma. Preclinical studies are underway to test CBN’s ability to provide neuroprotection as well as reduce intraocular pressure in the eye.
Learn More
Game-Changing Cannabinoid Manufacturing System
IntegraSyn™ is InMed’s integrated cannabinoid manufacturing system to efficiently produce bio-identical cannabinoids.
Learn More
Successful Track Record
InMed’s management team has a proven track record of success in delivering on its milestones and advancing new pharmaceutical therapies for diseases with high unmet medical needs.
Learn More

Expertise in the pharmaceutical development of rare cannabinoids

InMed is a clinical-stage pharmaceutical company focused on the development of rare cannabinoids to treat several diseases with high unmet medical needs.

Programs for skin and ocular disease

Two of InMed’s most advanced programs focus on rare cannabinoid formulations for skin and ocular diseases. Cannabinol (CBN), a rare cannabinoid, is the active pharmaceutical ingredient (API) in InMed’s two lead programs for epidermolysis bullosa and glaucoma. InMed’s INM-755 is a CBN topical cream under development for epidermolysis bullosa, a devastating, rare genetic skin disease. InMed has completed two Phase 1 clinical trials in healthy volunteers. InMed’s second program, INM-088, is a CBN-based product being developed as a topical ocular formulation for glaucoma and is currently in preclinical studies. Learn more about our programs in epidermolysis bullosa and glaucoma.

A goal to deliver safe and effective cannabinoid treatments

InMed’s preclinical studies of cannabinol (CBN) demonstrated an excellent safety profile. In preclinical studies, CBN showed the potential for therapeutic benefit over other cannabinoids such as tetrahydrocannabinol (THC) and cannabidiol (CBD). The findings from these extensive studies supported the advancement of INM-755 cream as an investigational treatment for epidermolysis bullosa (EB) into Phase 1 clinical studies in healthy volunteers. Two Phase 1 studies have been completed and plans are underway to file regulatory applications for a Phase 2 study in EB patients in several countries in the first half of 2021. 

learn More

Integrated cannabinoid manufacturing system to produce pharmaceutical-grade, bio-identical cannabinoids

While rare cannabinoids may hold tremendous potential as new treatments for diseases with high unmet medical needs, it is not economically feasible to extract and purify most of them directly from the plant due to the very low quantities available.

IntegraSynTM, InMed’s integrated cannabinoid manufacturing system, uses multiple standard pharmaceutical processes to enable the production of cannabinoids with bio-identical structures as compared to those found in nature.

learn More
Click to enlarge

Successful track record

InMed aims to transform patients’ lives by developing safe and effective cannabinoid-based therapeutics across a broad spectrum of diseases with high unmet medical needs.

Since our formation in 2014, we have fortified our capital position, assembled a world class leadership team with a successful track record in drug development, strengthened our potentially game-changing technologies, and advanced our novel, cannabinoid-based pipeline of drug candidates.

Today, InMed is acutely focused on building a technologically advanced cannabinoid pharmaceutical company unlike any other.

learn More

Latest News

InMed to Present at Virtual Conferences in March 2021

March 3, 2021
Learn More

InMed Announces Closing of US$4.5 Million Private Placement

February 16, 2021
Learn More

InMed Pharmaceuticals Reports Second Quarter Fiscal 2021 Financial Results

February 11, 2021
Learn More

InMed Pharmaceuticals to Report Second Quarter Fiscal 2021 Financial Results

February 6, 2021
Learn More

InMed Announces US$4.5 Million Private Placement

February 5, 2021
Learn More

InMed Pharmaceuticals to Participate in 2021 Cannabinoid-Derived Pharmaceuticals Industry Review Summit Europe

January 19, 2021
Learn More
See all news

Investor Alerts

Sign up to receive news releases from InMed Pharmaceuticals.
Learn More


INM-755

A cannabinol (CBN) cream under development for the treatment for Epidermolysis Bullosa
Learn More

INM-088

A cannabinol (CBN) formulation in preclinical development for the treatment of glaucoma
Learn More

IntegraSyn™

InMed’s flexible, integrated cannabinoid manufacturing system to efficiently produce pharmaceutical-grade, bio-identical cannabinoids.
Learn More
InMed-logo-mono
#310 – 815 West Hastings St.
Vancouver, BC, Canada
V6C 1B4
Science
  • INM-755 for Epidermolysis Bullosa
  • INM-088 for Glaucoma
  • IntegraSyn™ Cannabinoid Manufacturing
  • InMed’s Research of Rare Cannabinoids

Investor

  • News Releases
  • Latest Presentation
  • Letter to Shareholders
  • SEDAR® Filings
  • Financial Reports
  • Sign up for Investor Alerts

About

  • Management
  • Board of Directors
  • Scientific Advisory Board
  • Corporate Governance
  • Partners and Collaborators
  • Events Calendar
  • Careers

Learn

  • What is Cannabinol (CBN)?
  • What is Epidermolysis Bullosa (EB)?
  • What is Glaucoma?
  • GMP Manufacturing Standards by Product Type
  • Cannabinoids for Glaucoma
  • Cannabinoid Science
  • Articles and Videos

© Copyright 2021 InMed Pharmaceuticals Inc.

  • Privacy Policy
  • Terms of Use
  • Legal Disclaimer
  • Find Us On: